Tessari Eben 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
- Sale
Class A Ordinary Share
2025-11-17$41.30/sh−11,825$488,372→ 22,714 total - Exercise/Conversion
Class A Ordinary Share
2025-11-17$8.83/sh+6,500$57,395→ 35,184 total - Sale
Class A Ordinary Share
2025-11-17$40.08/sh−645$25,852→ 34,539 total - Exercise/Conversion
Share Option
2025-11-17−6,500→ 6,000 totalExercise: $8.83Exp: 2029-09-16→ Class A Ordinary Share (6,500 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.61 and $40.585. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.61 and $41.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F4]The option is fully vested and exercisable.